The case for & against
Bull & Bear analysis
Bearish
cbdMD, Inc. (NYSE American: YCBD) operates within the CBD sector, focusing on a diverse range of cannabidiol products, including oils, capsules, topicals, and innovative beverages like the Oasis brand. The company has strategically positioned itself in the consumer wellness market while navigating a complex regulatory landscape. cbdMD aims to capitalize on emerging opportunities in both health and wellness sectors, evidenced by its recent launch of the Oasis Mixer—a hemp-derived beverage designed for the growing functional alcohol alternative market.
Bull says
- ↑Q2 2026 net sales rose 19% YoY to $5.6 M, marking a fifth straight quarter of growth
- ↑Oasis Mixer hemp-derived beverage launch was oversubscribed, tapping into functional drink demand
- ↑Bluebird Botanicals integration set to flip from earnings drag to net positive in Q3
- ↑Proactive regulatory engagement may secure fairer federal treatment for hemp-derived products
- ↑Strong liquidity and cash flow support operations; 1.33% dividend yield attracts income investors
Bear says
- ↓Loss from operations widened to $801 K in Q2 despite revenue gains, signaling weak profitability
- ↓Cash used in operating activities hit $723 K in Q2, straining cash reserves
- ↓Shifting state regulations continue to narrow product offerings and confuse customers
- ↓Wholesale channel sales fell 17% YoY, exposing revenue volatility risk
- ↓Herbal Oasis line remains small; slow adoption could dent growth forecasts
- ↓Elevated leverage risk, weak profitability and momentum, plus high short interest weigh on outlook
Investment themes with YCBD
Pharmaceuticals↓ -0.08%
Drug development driving global healthcare solutions
LLY · JNJ · MRK
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q2 2026 · Mgmt. Guidance
Updated 05-20-2026neutral
Transcript signals
Bull points
- The second quarter of fiscal 2026 was another step forward for CBDMD and one of the most active quarters we've had in years, both operationally and across the regulatory landscape we operate in.
- Wholesale was up 65% year-over-year, reflected continued execution in our core CBDMD brand and ongoing progress with our Oasis THC beverage brand.
- We believe the long-term opportunity is significant, and we believe CBDMD's years of investment in manufacturing, quality, safety, and clinical research positions the company as a trusted, evidence-based supplier of choice as this channel develops.
Bear points
- As expected, the acquisition was a drag on earnings during the second quarter, where we absorbed transition costs and integration expenses without the full benefit of a full quarter of Bluebird revenue.
- That said, Bluebird turned the corner in March and began generating positive contribution, and we expect to flip that into positive for both top-line earnings and earnings in the third quarter as we roll out additional products and capture costs and revenue synergies.
- Changing rules across multiple states has driven ongoing packaging changes, repacking costs, and new testing requirements, each carrying real expenses and creating confusion at the customer level.
Read full transcript analysis ›